ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Pharmacoepidemiology"

  • Abstract Number: 0862 • ACR Convergence 2022

    Impact of the COVID-19 Pandemic on the Management of Juvenile Idiopathic Arthritis: An Analysis of National United States Administrative Claims Data

    Daniel Horton1, Yiling Yang2, Amanda Neikirk2, Cecilia Huang3, Stephen Crystal4, amy davidow5, Kevin Haynes6, Tobias Gerhard7, Carlos Rose8, Brian Strom9 and Lauren Parlett2, 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2HealthCore, Wilmington, DE, 3Rutgers Center for Pharmacoepidemiology and Treatment Science, New Brunswick, NJ, 4Rutgers Center for Health Services Research, New Brunswick, NJ, 5New York University, New York, NY, 6Johnson & Johnson, Titusville, NJ, 7Ernest Mario School of Pharmacy, Rutgers University, New Brunswick, NJ, 8Nemours, Chadds Ford, PA, 9Rutgers Biomedical and Health Sciences, Newark, NJ

    Background/Purpose: Limited information exists on COVID-19 pandemic-related changes in the management of rheumatic diseases in adults or children, besides what patients and families have reported.…
  • Abstract Number: 0925 • ACR Convergence 2022

    Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drugs on Pain Medication Use in Patients with Rheumatoid Arthritis

    Mengdong He1, Yvonne Lee2, Yinzhu Jin3, Rishi Desai3, Seanna Vine3 and Seoyoung Kim3, 1UCLA David Geffen School of Medicine, Los Angeles, CA, 2Northwestern University, Chicago, IL, 3Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Chronic pain associated with rheumatoid arthritis (RA) leads to impaired patient function and quality of life. Prior studies suggest initiation of disease-modifying antirheumatic drugs…
  • Abstract Number: 1112 • ACR Convergence 2022

    Biosimilar-to-Biosimilar Switching in Routine Care – Results on >1,600 Patients with Inflammatory Arthritis in the DANBIO Registry

    Hafsah Nabi1, Oliver Hendricks2, Dorte Vendelbo Jensen3, Anne Gitte Loft4, Jens Pedersen5, Søren Just6, Kamilla Danebod7, Heidi Munk8, Salome Kristensen9, Natalia Manilo10, Ada Colic11, Asta Linauskas12, Pia Høger Thygesen13, Louise Christensen3, Maren Høgberget Kalisz3, Niels Lomborg14, Stavros Chrysidis15, Johnny Raun15, Marlene Andersen16, Frank Mehnert17, Niels Steen Krogh18, Merete L Hetland19 and Bente Glintborg20, 1DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Copenhagen, Denmark, 2Danish Hospital For Rheumatic Diseases, Sønderborg, Denmark, 3Department of Rheumatology, Gentofte and Herlev Hospital, Copenhagen University Hospital, Gentofte, Denmark, 4Aarhus University, Horsens, Denmark, 5Svendborg Hospital, Odense University Hospital, Odense, Denmark, 6Medicinsk Afdeling Svendborg Sygehus OUH, Odense, Denmark, 7Department of Rheumatology, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark, 8Department of Rheumatology, Odense University Hospital, Odense, Denmark, Odense, Denmark, 9Center of Rheumatic Research Aalborg, Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, 10Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Denmark, 11Department of Rheumatology, Zealand University Hospital, Køge, Denmark, 12North Denmark Regional Hospital, Hjørring, Denmark, 13Department of Rheumatology, Slagelse Hospital, Slagelse, Denmark, 14Department of Rheumatology, Vejle Hospital Lillebælt, Vejle, Denmark, Odense, Denmark, 15Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, 16Department of Rheumatology, North Denmark Regional Hospital, Hjørring, Denmark, 17Aarhus University Hospital, Aarhus, Denmark, 18ZiteLab ApS, Frederiksberg, Denmark, 19Rigshospitalet, Glostrup, Denmark, 20Rigshospitalet, Glostrup, Virum, Denmark

    Background/Purpose: In routine care, biosimilar-to-biosimilar infliximab switching may occur to save costs (=non-medical switching). Previous studies have investigated the efficacy and safety of switches from…
  • Abstract Number: 1199 • ACR Convergence 2022

    Validation of New Medication User Definitions in Single-Specialty EHR Data

    Jeffrey Curtis1, Yujie Su2, Michael george3, Cassie Clinton2, Patrick Stewart4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3UPENN, Philadelphia, PA, 4Bendcare, Boca Raton, FL, 5FASTER, Hoover, AL

    Background/Purpose: New user designs are standard in many pharmacoepidemiology studies, but a first prescription appearance in electronic health record (EHR) data may not always represent…
  • Abstract Number: 1213 • ACR Convergence 2022

    Trends of Opioid Prescriptions and Impact of the COVID-19 Pandemic Among Patients with Musculoskeletal Diseases Between 2006-2021

    Joyce (Yun-Ting) Huang1, David Jenkins2, Belay Birlie Yimer1, Jose Benitez-Aurioles2, Niels Peek2, Mark Lunt1, Will Dixon3 and Meghna Jani1, 1Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, United Kingdom, 2Division of Informatics, The University of Manchester, Manchester, United Kingdom, 3The University of Manchester, Manchester, United Kingdom

    Background/Purpose: Opioid prescribing has contributed to a North American epidemic with increasing trends in several European countries. Rheumatic and musculoskeletal diseases (RMDs) are one of…
  • Abstract Number: 1374 • ACR Convergence 2022

    Real-World Effectiveness and Steroid Sparing Effect of Belimumab in Pediatric Lupus: A Single Center Retrospective Study

    Jordan Roberts1, Mindy Lo1, Rebecca Sadun2, Emily Smitherman3, Scott Wenderfer4 and Mary Beth F. Son1, 1Division of Immunology, Boston Children's Hospital, Boston, MA, 2Duke University, Durham, NC, 3University of Alabama at Birmingham, Birmingham, AL, 4British Columbia Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: Belimumab is the only targeted therapy approved for pediatric systemic lupus erythematosus (pSLE), although use remains limited in children. While clinical trials and studies…
  • Abstract Number: 1429 • ACR Convergence 2022

    Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study

    jacques-eric gottenberg1, Nadir Mammar2, Meriem Kessouri2, Jeremie RUDANT2, nada Assi3, Benjamin grenier3 and julien kirchgesner4, 1Strasbourg University Hospital, Strasbourg, France, 2Pfizer, Paris, France, 3HEVA, Lyon, France, 4AP-HP, Paris, France

    Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…
  • Abstract Number: 1546 • ACR Convergence 2022

    Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry

    Sebastian Sattui1, Zihan Wan2, Fenglong Xie2, Cassie Clinton2, Robyn Domsic1 and Jeffrey Curtis3, 1University of Pittsburgh, Pittsburgh, PA, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…
  • Abstract Number: 0060 • ACR Convergence 2022

    Lower Healthcare Costs for Commercially Insured Patients with Rheumatoid Arthritis in Remission

    Jeffrey Curtis1, Kathleen Fox2, Fenglong Xie3, Yujie Su3, David Collier4, Cassie Clinton3 and Hafiz Oko-osi5, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Strategic Health (formerly with Amgen), Thousand Oaks, CA, 3University of Alabama at Birmingham, Birmingham, AL, 4Amgen Inc., Simi Valley, CA, 5Gilead Sciences, Foster City, CA

    Background/Purpose: Rheumatoid arthritis (RA) affects about 1-2% of adults with annual US costs at $19 billion. Most studies evaluating cost of care have not had…
  • Abstract Number: 1547 • ACR Convergence 2022

    Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica

    Jeffrey Curtis1, Kerri Ford2, Stefano Fiore3, Danielle Isaman4, Lita Araujo5, Natalia Petruski-Ivleva6 and Fenglong Xie7, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Sanofi, Destin, FL, 3Sanofi, Bridgewater, NJ, 4Sanofi, Chapel Hill, NC, 5Sanofi, Cambridge, MA, 6Sanofi, Unknown, 7University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Interleukin-6 receptor (IL-6R) inhibition has been shown to be effective in giant cell arteritis but data are limited in polymyalgia rheumatica (PMR). We conducted…
  • Abstract Number: 0074 • ACR Convergence 2022

    Real-World Treatment Patterns, Healthcare Resource Utilization (HCRU) and Costs in Patients with Systemic Lupus Erythematosus (SLE) in the US

    Prajakta Masurkar1, Jennifer Reckleff2, Nicole Princic3, Brendan Limone4, Hana Schwartz4, Elaine Karis5, Eric Zollars6, Bradley Stolshek5 and Karen Costenbader7, 1Amgen, Wylie, TX, 2Amgen, Westlake Village, CA, 3IBM Watson Health, Reading, MA, 4IBM Watson Health, Bethesda, MD, 5Amgen, Inc., Thousand Oaks, CA, 6Amgen, Newbury Park, CA, 7Brigham and Women's Hospital, Boston, MA

    Background/Purpose: SLE treatment is complex, with a wide variety of medications commonly prescribed. Limited evidence exists in the literature with respect to treatment patterns, HCRU…
  • Abstract Number: 1643 • ACR Convergence 2022

    Use of Oral Analgesics and Risk of Comorbidities in Osteoarthritis: Findings from Primary Care Settings in the UK

    Subhashisa Swain1, Carol Coupland2, Anne Kamps3, Jos Runhaar4, Andrea Dell ‘Isola5, Aleksandra Turkiewicz5, Danielle E Robinson1, Victoria Y Strauss1, Christian Mallen6, Chang-Fu Kuo7, Aliya Sarmanova8, Daniel Prieto Alhambra1, Martin Englund5, Sita Bierma-Zeinstra3, Michael Doherty2 and Weiya Zhang2, 1University of Oxford, Oxford, United Kingdom, 2University of Nottingham, Nottingham, United Kingdom, 3Erasmus University Medical Centre, Rotterdam, Netherlands, 4Erasmus Medical Center, Rotterdam, Netherlands, 5Lund University, Lund, Sweden, 6Keele University, Keele, United Kingdom, 7Chang Gung Memorial Hospital, Taoyuan, Taiwan, 8University of Bristol, Bristol, United Kingdom

    Background/Purpose: People with osteoarthritis (OA) often have multiple other conditions (comorbidities).Role of different oral analgesics on the development of comorbidities in people with OA have…
  • Abstract Number: 0245 • ACR Convergence 2022

    Influence of Forced Vital Capacity Impairment on Treatment Selection and Outcomes in RA-ILD Patients Initiating a Biologic or Targeted-Synthetic DMARD

    Bryant England1, Michael George2, Yangyuna Yang1, Punyasha Roul3, Jorge Rojas4, Brian Sauer5, Grant Cannon6, Joshua Baker7, Jeffrey Curtis8 and Ted Mikuls9, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3UNMC, Omaha, NE, 4George E. Wahlen Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, UT, 5Salt Lake City VA/University of Utah, Salt Lake City, UT, 6Salt Lake City VA, Salt Lake city, 7University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, 8Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 9Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Patients with RA-associated interstitial lung disease (RA-ILD) suffer from substantial morbidity and premature mortality. The optimal use of biologic/tsDMARDs in this population is poorly…
  • Abstract Number: 1648 • ACR Convergence 2022

    Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

    Eiichi Tanaka1, Ryoko Sakai2, Eisuke Inoue3 and Masayoshi Harigai1, 1Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 2Meiji Pharmaceutical University, Tokyo, Japan, 3Research Administration Center, Showa University, Shinagawa-ku, Japan

    Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…
  • Abstract Number: 0290 • ACR Convergence 2022

    Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the

    Kim Lauper1, Romain Aymon2, Denis Mongin2, Sytske Anne Bergstra3, Denis Choquette4, Catalin Codreanu5, Ori Elkayam6, Kimme Hyrich7, Florenzo Iannone8, Nevsun Inanc9, Lianne Kearsley-Fleet10, Tore K. kvien11, Eirik Kristianslund12, Burkhard Leeb13, Galina Lukina14, Dan Nordstrom15, Karel Pavelka16, Manuel Pombo-Suarez17, Ziga Rotar18, Maria José Santos19, Delphine Courvoisier20 and Axel Finckh21, 1Geneva University Hospitals, Genéve, Switzerland, 2Geneva University Hospitals, Geneva, Switzerland, 3LUMC, Leiden, Netherlands, 4Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada, 5Center for Rheumatic Diseases, Bucharest, Romania, 6Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 7The University of Manchester, Manchester, United Kingdom, 8School of Medicine University of Bari, Bari, Italy, 9Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, 10Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom, 11Diakonhjemmet Hospital, Oslo, Norway, 12Diakonhjemmet Hospital, Division of Rheumatology and Research, Oslo, Norway, 13Bioreg, Stockerau, Austria, 14Federal state budgetary scientific institution �Research Institute of rheumatology named after V. A. Nasonova�, Moscow, Russia, 15Helsinki University Hospital, Helsinki, Finland, 16Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Praha, Czech Republic, 17Hospital Clinico Universitario, Santiago de Compostela, Spain, 18University Medical Centre Ljubljana, Ljubljana, Slovenia, 19Hospital Garcia de Orta, Almada, Charneca da Caparica, Portugal, 20University Hospitals of Geneva, Geneva, Switzerland, 21Geneva University Hospital, Geneve - Vesenaz, Switzerland

    Background/Purpose: The "ORAL Surveillance" study1 suggests an increased risk of serious adverse events (AEs) with tofacitinib, a JAK-inhibitor (JAKi), compared to TNF-inhibitors (TNFi). Currently, there…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences